NUEDEXTA is an innovative
combination of two well-characterized components31,33,35,39

Quinidine increases dextromethorphan (DM) bioavailability greater than 20-fold and prolongs elimination half-life of DM from ~2 hours to 13 hours5,31,33,35 

Quinidine (10 mg) changes the exposure of dextromethorphan relative to its metabolite dextromorphan5,31,33,35

The exact mechanism by which NUEDEXTA exerts its therapeutic effects in
 patients with PBA is unknown.31

  • DEXTROMETHORPHAN HBr (20 mg)

    An uncompetitive NMDA receptor antagonist and sigma 1 receptor agonist, thought to act in the CNS to reduce PBA episodes

  • QUINIDINE SULFATE (10 mg)
    ultra-low dose32

    A metabolic inhibitor that increases DM exposure (>20 fold) and prolongs the elimination half-life of dextromethorphan by inhibiting its rapid conversion to dextrorphan

NUEDEXTA contains an ultra-low dose of quinidine (10 mg)

The 20-mg daily dose of quinidine is 1/30 of the lowest recommended antiarrhythmic dose of quinidine (600–1600 mg/day)20

Quinidine daily dosage

Quinidine daily dosage

 

 

 

 

How Nuedexta works video

Watch video

See the pharmacology of NUEDEXTA (3:20)

The exact mechanism by which NUEDEXTA exerts its therapeutic effects in patients with PBA is unknown.31

NUEDEXTA exhibits multifaceted pharmacology

NUEDEXTA is believed to modulate glutamate signaling41

Dextromethorphan is a sigma-1 receptor agonist and an uncompetitive NMDA receptor antagonist.6,10,23,25,26,30,38,41,46

NONCLINICAL STUDIES SUGGEST OTHER POTENTIAL RECEPTOR TARGETS:

  • Serotonin reuptake inhibition19,27
  • Norepinephrine reuptake inhibition11
  • Nicotinic α3ß4 ion channel antagonism16


The exact mechanism by which NUEDEXTA exerts its therapeutic effects in patients with PBA is unknown.31

How Nuedexta®  (dextromethorphan hydrobromide and quinidine sulfate) Works